TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11792748

Group type: EXPERIMENTAL
Intervention: HPV testing at 1.0 pg/mL threshold for ASCUS
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Repeat cytopathology for ASCUS in women aged 29 years or older
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: HPV testing at 10.0 pg/mL threshold for ASCUS
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Any strategy achieving 90% sensitivity for LSIL
Number of subjects: 3046
Study: 10964827

Group type: EXPERIMENTAL
Intervention: Nonpenetrating deep sclerectomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 39
Study: 8629604

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1479390

Group type: EXPERIMENTAL
Intervention: Head-free condition
Number of subjects: 7

Group type: COMPARATOR
Intervention: Head-fixed condition
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Active head movements in darkness (labyrinthine-deficient patients)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cerebellar degeneration and vestibular failure
Number of subjects: 7
Study: 6531969

Group type: EXPERIMENTAL
Intervention: RA 27/3 strain rubella vaccine (Rudivax)
Number of subjects: 326
Study: 30520252

Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 467

Group type: COMPARATOR
Intervention: Insulin Glargine (IG)
Number of subjects: 467
Study: 30288156

Group type: EXPERIMENTAL
Intervention: FDC tablet (gemigliptin/metformin SR 50/1,000 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Co-administration of individual tablets (gemigliptin 50 mg and metformin XR 1,000 mg)
Number of subjects: 24
Study: 27650124

Group type: EXPERIMENTAL
Intervention: ω‐3 polyunsaturated fatty acids (PUFAs) treatment for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: ARMS subjects who transitioned to psychotic disorder
Number of subjects: 39

Group type: COMPARATOR
Intervention: ARMS subjects who did not transition to psychotic disorder
Number of subjects: 39
Study: 25379431

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) administration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 16
Study: 22950641

Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated membrane (VEM) dialyzer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Simvastatin (10 mg daily)
Number of subjects: 10
Study: 20088695

Group type: EXPERIMENTAL
Intervention: 12-week treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 24-week treatment
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Suboptimal drug concentrations
Number of subjects: 303
Study: 18852484

Group type: EXPERIMENTAL
Intervention: 2 g of Ascorbic Acid (AA)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 150 mg of iron carbonyl
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 g of Ascorbic Acid (AA) plus 150 mg of iron carbonyl
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 9
Study: 15733070

Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) treatment for 24 hours
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: High-dose glucose-insulin-potassium (GIK) treatment
Number of subjects: 74
Study: 12538178

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% dextran 70 (DEX)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6% hetastarch (HES)
Number of subjects: 40
Study: 10664047

Group type: EXPERIMENTAL
Intervention: Latanoprost, 0.005% once daily
Number of subjects: 183

Group type: COMPARATOR
Intervention: Combination of timolol, 0.5% twice daily, and dorzolamide, 2% twice daily
Number of subjects: 183
Study: 8703857

Group type: EXPERIMENTAL
Intervention: Isocapnic hyperoxia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study: 1539069

Group type: EXPERIMENTAL
Intervention: Acetaminophen (0, 325, 650, 1300 or 1950 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol (total dose = 0.625 g/kg; five divided doses)
Number of subjects: 6
Study: 28139153

Group type: EXPERIMENTAL
Intervention: Test pudding (12.9g WP and 6g PX)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control pudding
Number of subjects: 25
Study: 24842476

Group type: EXPERIMENTAL
Intervention: CZP 200 mg and methotrexate (J-RAPID trial)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: CZP 200 mg alone or with disease-modifying agents other than methotrexate (HIKARI trial)
Number of subjects: 198

Group type: COMPARATOR
Intervention: DAS28(ESR) response < 1.2 at week 12
Number of subjects: 198
Study: 23044532

Group type: EXPERIMENTAL
Intervention: Scheduled deep brain stimulation (DBS)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Acute scheduled vs acute continuous vs off DBS
Number of subjects: 5
Study: 21136109

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (LPS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study: 19509031

Group type: EXPERIMENTAL
Intervention: Community based environmental management approach combined with routine Aedes control programme
Number of subjects: 64000

Group type: COMPARATOR
Intervention: Routine Aedes control programme (entomological surveillance, source reduction, selective adulticiding, and health education)
Number of subjects: 64000
Study: 17517832

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b monotherapy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b plus lamivudine combination therapy
Number of subjects: 48
Study: 15213566

Group type: EXPERIMENTAL
Intervention: HAART‐MMF group (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: HAART group (n = 6)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Inhibition group (n = 6)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No inhibition group (n = 9)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HAART‐MMF group
Number of subjects: 17
Study: 11481357

Group type: EXPERIMENTAL
Intervention: ADocT (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 with tamoxifen)
Number of subjects: 250

Group type: COMPARATOR
Intervention: ADoc (doxorubicin 50 mg/m2 and docetaxel 75 mg/m2 without tamoxifen)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: ADocT
Number of subjects: 250

Group type: COMPARATOR
Intervention: ADoc
Number of subjects: 250
Study: 9707742

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg in children or 500 mg/day in adults for 3 days)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (standard doses for 7 to 14 days)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Cefaclor (standard doses for 7 to 14 days)
Number of subjects: 145
Study: 7915289

Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 509
Study: 3133266

Group type: EXPERIMENTAL
Intervention: Insulin + Glibenclamide (15 mg per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin + Placebo
Number of subjects: 15
Study: 31150451

Group type: EXPERIMENTAL
Intervention: Transitional health management for three months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no transitional health management)
Number of subjects: 150
Study: 28446376

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exergaming Program (WII Group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Home Exercise Program (EX Group)
Number of subjects: 30
Study: 26042933

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus lomustine
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lomustine single agent
Number of subjects: 141

Group type: COMPARATOR
Intervention: Bevacizumab single agent
Number of subjects: 141
Study: 23674066

Group type: EXPERIMENTAL
Intervention: White wheat bread fortified with bioprocessed rye bran
Number of subjects: 15

Group type: COMPARATOR
Intervention: Native rye bran
Number of subjects: 15

Group type: COMPARATOR
Intervention: Wholegrain rye bread
Number of subjects: 15

Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 15
Study: 21671744

Group type: EXPERIMENTAL
Intervention: Increased activation in functionally defined insula/middle frontal gyrus when viewing pity targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased activation in anatomically defined bilateral anterior insula in response to positive events
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotypes' specific content
Number of subjects: 0
Study: 19212103

Group type: EXPERIMENTAL
Intervention: Pre-surgical aerobic exercise training at 40 to 65% of heart rate reserve (%HRR) for 3.8 +/- 1.2 weeks (27 +/- 8 sessions)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pre-surgical aerobic exercise training at 40 to 65% of heart rate reserve (%HRR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both groups (exercise and control)
Number of subjects: 21
Study: 18062847

Group type: EXPERIMENTAL
Intervention: Criticism from an out-group member; participants reported being more defensive when evaluations were private.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criticism from an in-group member; participants' evaluations could be seen by an in-group audience.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Criticism from an in-group member; high-status in-group audience.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Public evaluations of criticism from an in-group critic.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Public evaluations of criticism from an out-group critic.
Number of subjects: 0
Study: 15617458

Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Losartan 50-100 mg
Number of subjects: 180
Study: 11320384

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9298865

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7509481

Group type: EXPERIMENTAL
Intervention: ECMO infants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy term control infants
Number of subjects: 40
Study: 3312204

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 200
Study: 31109652

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once weekly (qw)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1379
Study: 29518295

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (1.0 ml) and injectable water (1.5 ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bupivacaine (1 ml, 5 mg/ml) and injectable water (1.5 ml)
Number of subjects: 20
Study: 25602496

Group type: EXPERIMENTAL
Intervention: Chlorhexidine bathing (2% chlorhexidine)
Number of subjects: 9340

Group type: COMPARATOR
Intervention: Nonantimicrobial cloths (control)
Number of subjects: 9340
Study: 24070808

Group type: EXPERIMENTAL
Intervention: Bilateral Tecnis ZM900 diffractive multifocal lenses
Number of subjects: 212

Group type: COMPARATOR
Intervention: Akreos AO monofocal lenses
Number of subjects: 212
Study: 20521858

Group type: EXPERIMENTAL
Intervention: Self-projection to the personal past
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observing another person's perspective
Number of subjects: 0
Study: 19586971

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Predialysis blood pressure measurements
Number of subjects: 65
Study: 17596110

Group type: EXPERIMENTAL
Intervention: Darunavir/r (400/100mg twice daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atazanavir/r (300/100mg once daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Darunavir/r (400/100mg twice daily) plus Atazanavir (300mg once daily)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Darunavir/r, Atazanavir/r, or Darunavir/r plus Atazanavir regimens
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atazanavir-containing regimens
Number of subjects: 23
Study: 16334443

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (amoxicillin, tetracycline, metronidazole) for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 20
Study: 11786577

Group type: EXPERIMENTAL
Intervention: COPP/ABV/IMEP
Number of subjects: 996

Group type: COMPARATOR
Intervention: COPP/ABVD
Number of subjects: 996
Study: 9800180

Group type: EXPERIMENTAL
Intervention: Hearing Conservation Program (HCP)
Number of subjects: 753

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 753
Study: 7636076

Group type: EXPERIMENTAL
Intervention: Tutorial plus a simulation test (group 2)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Drill-and-practice program plus a simulation test (group 1)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Simulation test only (group 3)
Number of subjects: 413
Study: 1699689

Group type: EXPERIMENTAL
Intervention: GHRH (hpGRF(1‐29), 1 microgram/kg i.v.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gal (15 micrograms/kg/h for 1 h) plus GHRH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gal (15 micrograms/kg/h for 1 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gal plus GHRH
Number of subjects: 12
Study: 346192

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy (Vinblastin 6 mg/m2, Thiotepa 6 mg/m2, Rufocromomycine 60 microgram/m2, Methotrexate 15 mg/m2, Procarbazine 30 mg/m2)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (DTIC 80 mg/kg for ten days)
Number of subjects: 117
Study: 31991037

Group type: EXPERIMENTAL
Intervention: 3D‐EAUS
Number of subjects: 68

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intra‐operative exploration
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (HO)‐enhanced 3D‐EAUS
Number of subjects: 68
Study: 31111862

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut sirolimus-eluting stents
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Very thin-strut everolimus-eluting stents
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Thin-strut zotarolimus-eluting stents
Number of subjects: 1506
Study: 28950305

Group type: EXPERIMENTAL
Intervention: Cetuximab plus cisplatin (CetCis)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Cetuximab plus cisplatin plus paclitaxel (CetCisPac)
Number of subjects: 201
Study: 25294735

Group type: EXPERIMENTAL
Intervention: Guided plasticity training starting the first week after surgery with sensory and motor re-learning using mirror visual feedback and observation of touch
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group with re-learning starting when reinnervation could be detected
Number of subjects: 37
Study: 24239156

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/daily for 30 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/daily for 30 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Bergamot-derived polyphenolic fraction (BPF) 1000 mg/daily for 30 days
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: BPF 1000 mg/daily plus rosuvastatin 10 mg/daily for 30 days
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 21888660

Group type: EXPERIMENTAL
Intervention: State-of-the-art strategy (education, reminders, feedback, adequate products and facilities)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Extended strategy (includes all elements of the state-of-the-art strategy plus social influence, leadership, commitment, norms, and targets)
Number of subjects: 900
Study: 18649820

Group type: EXPERIMENTAL
Intervention: Programmable medication devices (dispensers and timers)
Number of subjects: 33
Study: 17053341

Group type: EXPERIMENTAL
Intervention: Individual LDT session
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Group LDT session
Number of subjects: 23

Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 23
Study: 15248415

Group type: EXPERIMENTAL
Intervention: Intravenous amoxicillin plus clavulanic acid (2.2 g) administered 10 minutes before tonsillectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral amoxicillin-clavulanic acid (3 doses the day before surgery, plus one oral administration 2 hours before tonsillectomy)
Number of subjects: 50
Study: 11086366

Group type: EXPERIMENTAL
Intervention: Stratified care (n = 279) with aspirin 800 to 1000 mg plus metoclopramide 10 mg for MIDAS grade II and zolmitriptan 2.5 mg for MIDAS grade III and IV.
Number of subjects: 835

Group type: COMPARATOR
Intervention: Step care across attacks (n = 271) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 10 mg, switching to zolmitriptan 2.5 mg if not responding in at least 2 of the first 3 attacks.
Number of subjects: 835

Group type: COMPARATOR
Intervention: Step care within attacks (n = 285) with initial treatment of aspirin 800 to 1000 mg plus metoclopramide 20 mg, escalating to zolmitriptan 2.5 mg if not responding after 2 hours.
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Stratified care (n = 279)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Step care across attacks (n = 271)
Number of subjects: 835

Group type: COMPARATOR
Intervention: Step care within attacks (n = 285)
Number of subjects: 835
Study: 9282965

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 8442969

Group type: COMPARATOR
Intervention: Succinylcholine 0.5 mg/kg after no pretreatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after d‐tubocurarine 0.05 mg/kg IV 3 minutes before
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after chlorpromazine 0.1 mg/kg IV 3 minutes before
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after alpha‐tocopherol (vitamin E) 600 mg in three divided doses orally at 6‐hour intervals
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Succinylcholine 0.5 mg/kg after aspirin 600 mg orally 1 hour before
Number of subjects: 50
Study: 3089491

Group type: EXPERIMENTAL
Intervention: linoleic acid
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 31558086

Group type: EXPERIMENTAL
Intervention: Pulse-based diet (lentils, beans, split peas, and chickpeas) with health counseling and aerobic exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Therapeutic Lifestyle Changes (TLC) diet with health counseling and aerobic exercise
Number of subjects: 61
Study: 28549873

Group type: EXPERIMENTAL
Intervention: Topical Betadine (Povidone‐iodine)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Topical Clotrimazole
Number of subjects: 204
Study: 27464488

Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Physical Activity and Dietary Intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Less Intensive Intervention
Number of subjects: 260
Study: 24435584

Group type: EXPERIMENTAL
Intervention: IVR + coach
Number of subjects: 71

Group type: COMPARATOR
Intervention: IVR + no-coach
Number of subjects: 71
Study: 23439339

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 20
Study: 21474462

Group type: EXPERIMENTAL
Intervention: Highly purified omega-3 polyunsaturated fatty acid ethyl esters (n-3 PUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18424298

Group type: EXPERIMENTAL
Intervention: Endoscopic hematoma evacuation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 10
Study: 16515902

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Heparin with protamine reversal
Number of subjects: 150
Study: 14747047

Group type: EXPERIMENTAL
Intervention: Androgen blockade with 4 cycles of immediate chemotherapy
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Androgen blockade with delayed chemotherapy
Number of subjects: 30000
Study: 11109313

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT) with 17-beta-estradiol and noretisterone acetate, TTS for 3 months.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no HRT) for 3 months.
Number of subjects: 53
Study: 9195357

Group type: COMPARATOR
Intervention: Controlled hypotension alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hemodilution plus controlled hypotension
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hemodilution alone
Number of subjects: 30
Study: 8266412

Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 0
Study: 3313739

Group type: EXPERIMENTAL
Intervention: Mefloquine 750 mg, sulfadoxine 1500 mg and pyrimethamine 75 mg (MSP) single oral dose
Number of subjects: 66

Group type: COMPARATOR
Intervention: Quinine (10 mg/kg tds X 7 days oral therapy)
Number of subjects: 66
Study: 31900583

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 3217

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 3217
Study: 30269900

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331

Group type: EXPERIMENTAL
Intervention: CKD presence
Number of subjects: 2331
Study: 27327024

Group type: COMPARATOR
Intervention: High-CHO (HCHO): 10 g·kg CHO, 2.5 g·kg protein, and 0.8 g·kg fat for the entire trial period
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reduced-CHO but high-fat availability (HFAT): 2.5 g·kg CHO, 2.5 g·kg protein, and 3.5 g·kg fat for the entire trial period
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-CHO (HCHO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Reduced-CHO but high-fat availability (HFAT)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-CHO (HCHO) and Reduced-CHO but high-fat availability (HFAT)
Number of subjects: 10